nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—Thrombophlebitis—Mitomycin—urinary bladder cancer	0.0299	0.0299	CcSEcCtD
Methylergometrine—Haematuria—Valrubicin—urinary bladder cancer	0.0276	0.0276	CcSEcCtD
Methylergometrine—Chest pain—Valrubicin—urinary bladder cancer	0.0193	0.0193	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.0151	0.0151	CcSEcCtD
Methylergometrine—Abdominal pain—Valrubicin—urinary bladder cancer	0.0146	0.0146	CcSEcCtD
Methylergometrine—Hypertension—Mitomycin—urinary bladder cancer	0.0134	0.0134	CcSEcCtD
Methylergometrine—Diarrhoea—Valrubicin—urinary bladder cancer	0.0126	0.0126	CcSEcCtD
Methylergometrine—Thrombophlebitis—Fluorouracil—urinary bladder cancer	0.0124	0.0124	CcSEcCtD
Methylergometrine—Dizziness—Valrubicin—urinary bladder cancer	0.0122	0.0122	CcSEcCtD
Methylergometrine—Vomiting—Valrubicin—urinary bladder cancer	0.0117	0.0117	CcSEcCtD
Methylergometrine—Rash—Valrubicin—urinary bladder cancer	0.0116	0.0116	CcSEcCtD
Methylergometrine—Dermatitis—Valrubicin—urinary bladder cancer	0.0116	0.0116	CcSEcCtD
Methylergometrine—Headache—Valrubicin—urinary bladder cancer	0.0116	0.0116	CcSEcCtD
Methylergometrine—Dyspnoea—Mitomycin—urinary bladder cancer	0.0113	0.0113	CcSEcCtD
Methylergometrine—Nasal congestion—Cisplatin—urinary bladder cancer	0.0112	0.0112	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Gemcitabine—urinary bladder cancer	0.0112	0.0112	CcSEcCtD
Methylergometrine—Nausea—Valrubicin—urinary bladder cancer	0.011	0.011	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Cisplatin—urinary bladder cancer	0.0104	0.0104	CcSEcCtD
Methylergometrine—Haematuria—Thiotepa—urinary bladder cancer	0.00956	0.00956	CcSEcCtD
Methylergometrine—Angina pectoris—Fluorouracil—urinary bladder cancer	0.00906	0.00906	CcSEcCtD
Methylergometrine—Hallucination—Thiotepa—urinary bladder cancer	0.00895	0.00895	CcSEcCtD
Methylergometrine—Diarrhoea—Mitomycin—urinary bladder cancer	0.0087	0.0087	CcSEcCtD
Methylergometrine—Sweating increased—Cisplatin—urinary bladder cancer	0.00859	0.00859	CcSEcCtD
Methylergometrine—Dizziness—Mitomycin—urinary bladder cancer	0.00841	0.00841	CcSEcCtD
Methylergometrine—Tinnitus—Thiotepa—urinary bladder cancer	0.00839	0.00839	CcSEcCtD
Methylergometrine—Cardiac disorder—Thiotepa—urinary bladder cancer	0.00835	0.00835	CcSEcCtD
Methylergometrine—Vomiting—Mitomycin—urinary bladder cancer	0.00808	0.00808	CcSEcCtD
Methylergometrine—Haematuria—Gemcitabine—urinary bladder cancer	0.00804	0.00804	CcSEcCtD
Methylergometrine—Rash—Mitomycin—urinary bladder cancer	0.00802	0.00802	CcSEcCtD
Methylergometrine—Dermatitis—Mitomycin—urinary bladder cancer	0.00801	0.00801	CcSEcCtD
Methylergometrine—Headache—Mitomycin—urinary bladder cancer	0.00796	0.00796	CcSEcCtD
Methylergometrine—Sweating increased—Etoposide—urinary bladder cancer	0.00787	0.00787	CcSEcCtD
Methylergometrine—Nausea—Mitomycin—urinary bladder cancer	0.00755	0.00755	CcSEcCtD
Methylergometrine—Atrioventricular block—Epirubicin—urinary bladder cancer	0.00744	0.00744	CcSEcCtD
Methylergometrine—Ventricular tachycardia—Epirubicin—urinary bladder cancer	0.00722	0.00722	CcSEcCtD
Methylergometrine—Bradycardia—Cisplatin—urinary bladder cancer	0.00718	0.00718	CcSEcCtD
Methylergometrine—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.00703	0.00703	CcSEcCtD
Methylergometrine—Atrioventricular block—Doxorubicin—urinary bladder cancer	0.00688	0.00688	CcSEcCtD
Methylergometrine—Convulsion—Thiotepa—urinary bladder cancer	0.00679	0.00679	CcSEcCtD
Methylergometrine—Hypertension—Thiotepa—urinary bladder cancer	0.00676	0.00676	CcSEcCtD
Methylergometrine—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.00668	0.00668	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Epirubicin—urinary bladder cancer	0.00663	0.00663	CcSEcCtD
Methylergometrine—Tinnitus—Cisplatin—urinary bladder cancer	0.00658	0.00658	CcSEcCtD
Methylergometrine—Cardiac disorder—Cisplatin—urinary bladder cancer	0.00655	0.00655	CcSEcCtD
Methylergometrine—Thrombophlebitis—Methotrexate—urinary bladder cancer	0.00647	0.00647	CcSEcCtD
Methylergometrine—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00627	0.00627	CcSEcCtD
Methylergometrine—Tachycardia—Thiotepa—urinary bladder cancer	0.00624	0.00624	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Doxorubicin—urinary bladder cancer	0.00613	0.00613	CcSEcCtD
Methylergometrine—Thrombophlebitis—Epirubicin—urinary bladder cancer	0.00605	0.00605	CcSEcCtD
Methylergometrine—Cardiac disorder—Etoposide—urinary bladder cancer	0.006	0.006	CcSEcCtD
Methylergometrine—Muscle spasms—Cisplatin—urinary bladder cancer	0.00591	0.00591	CcSEcCtD
Methylergometrine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00574	0.00574	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.00571	0.00571	CcSEcCtD
Methylergometrine—Hypertension—Gemcitabine—urinary bladder cancer	0.00569	0.00569	CcSEcCtD
Methylergometrine—Convulsion—Fluorouracil—urinary bladder cancer	0.00561	0.00561	CcSEcCtD
Methylergometrine—Chest pain—Gemcitabine—urinary bladder cancer	0.00561	0.00561	CcSEcCtD
Methylergometrine—Thrombophlebitis—Doxorubicin—urinary bladder cancer	0.0056	0.0056	CcSEcCtD
Methylergometrine—Chest pain—Fluorouracil—urinary bladder cancer	0.00552	0.00552	CcSEcCtD
Methylergometrine—Muscle spasms—Etoposide—urinary bladder cancer	0.00541	0.00541	CcSEcCtD
Methylergometrine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00538	0.00538	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.00535	0.00535	CcSEcCtD
Methylergometrine—Convulsion—Cisplatin—urinary bladder cancer	0.00532	0.00532	CcSEcCtD
Methylergometrine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00529	0.00529	CcSEcCtD
Methylergometrine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00527	0.00527	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00523	0.00523	CcSEcCtD
Methylergometrine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.0052	0.0052	CcSEcCtD
Methylergometrine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00519	0.00519	CcSEcCtD
Methylergometrine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00516	0.00516	CcSEcCtD
Methylergometrine—Abdominal pain—Thiotepa—urinary bladder cancer	0.00505	0.00505	CcSEcCtD
Methylergometrine—Hypotension—Gemcitabine—urinary bladder cancer	0.00503	0.00503	CcSEcCtD
Methylergometrine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00501	0.00501	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00495	0.00495	CcSEcCtD
Methylergometrine—Hypotension—Fluorouracil—urinary bladder cancer	0.00494	0.00494	CcSEcCtD
Methylergometrine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00492	0.00492	CcSEcCtD
Methylergometrine—Tachycardia—Cisplatin—urinary bladder cancer	0.00489	0.00489	CcSEcCtD
Methylergometrine—Convulsion—Etoposide—urinary bladder cancer	0.00488	0.00488	CcSEcCtD
Methylergometrine—Hypertension—Etoposide—urinary bladder cancer	0.00486	0.00486	CcSEcCtD
Methylergometrine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00485	0.00485	CcSEcCtD
Methylergometrine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00483	0.00483	CcSEcCtD
Methylergometrine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.0048	0.0048	CcSEcCtD
Methylergometrine—Chest pain—Etoposide—urinary bladder cancer	0.00479	0.00479	CcSEcCtD
Methylergometrine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00475	0.00475	CcSEcCtD
Methylergometrine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00471	0.00471	CcSEcCtD
Methylergometrine—Hypotension—Cisplatin—urinary bladder cancer	0.00468	0.00468	CcSEcCtD
Methylergometrine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00459	0.00459	CcSEcCtD
Methylergometrine—Paraesthesia—Cisplatin—urinary bladder cancer	0.0045	0.0045	CcSEcCtD
Methylergometrine—Tachycardia—Etoposide—urinary bladder cancer	0.00448	0.00448	CcSEcCtD
Methylergometrine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00447	0.00447	CcSEcCtD
Methylergometrine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00444	0.00444	CcSEcCtD
Methylergometrine—Angina pectoris—Epirubicin—urinary bladder cancer	0.00441	0.00441	CcSEcCtD
Methylergometrine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00437	0.00437	CcSEcCtD
Methylergometrine—Hypotension—Etoposide—urinary bladder cancer	0.00429	0.00429	CcSEcCtD
Methylergometrine—Dizziness—Thiotepa—urinary bladder cancer	0.00423	0.00423	CcSEcCtD
Methylergometrine—Paraesthesia—Etoposide—urinary bladder cancer	0.00412	0.00412	CcSEcCtD
Methylergometrine—Haematuria—Methotrexate—urinary bladder cancer	0.00411	0.00411	CcSEcCtD
Methylergometrine—Dyspnoea—Etoposide—urinary bladder cancer	0.00409	0.00409	CcSEcCtD
Methylergometrine—Angina pectoris—Doxorubicin—urinary bladder cancer	0.00408	0.00408	CcSEcCtD
Methylergometrine—Vomiting—Thiotepa—urinary bladder cancer	0.00407	0.00407	CcSEcCtD
Methylergometrine—Rash—Thiotepa—urinary bladder cancer	0.00403	0.00403	CcSEcCtD
Methylergometrine—Dermatitis—Thiotepa—urinary bladder cancer	0.00403	0.00403	CcSEcCtD
Methylergometrine—Headache—Thiotepa—urinary bladder cancer	0.00401	0.00401	CcSEcCtD
Methylergometrine—Haematuria—Epirubicin—urinary bladder cancer	0.00385	0.00385	CcSEcCtD
Methylergometrine—Nausea—Thiotepa—urinary bladder cancer	0.0038	0.0038	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00376	0.00376	CcSEcCtD
Methylergometrine—Bradycardia—Epirubicin—urinary bladder cancer	0.00369	0.00369	CcSEcCtD
Methylergometrine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00368	0.00368	CcSEcCtD
Methylergometrine—Abdominal pain—Etoposide—urinary bladder cancer	0.00363	0.00363	CcSEcCtD
Methylergometrine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00362	0.00362	CcSEcCtD
Methylergometrine—Tinnitus—Methotrexate—urinary bladder cancer	0.00361	0.00361	CcSEcCtD
Methylergometrine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00359	0.00359	CcSEcCtD
Methylergometrine—Haematuria—Doxorubicin—urinary bladder cancer	0.00356	0.00356	CcSEcCtD
Methylergometrine—Dizziness—Fluorouracil—urinary bladder cancer	0.0035	0.0035	CcSEcCtD
Methylergometrine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00343	0.00343	CcSEcCtD
Methylergometrine—Vomiting—Gemcitabine—urinary bladder cancer	0.00342	0.00342	CcSEcCtD
Methylergometrine—Bradycardia—Doxorubicin—urinary bladder cancer	0.00341	0.00341	CcSEcCtD
Methylergometrine—Rash—Gemcitabine—urinary bladder cancer	0.00339	0.00339	CcSEcCtD
Methylergometrine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00339	0.00339	CcSEcCtD
Methylergometrine—Tinnitus—Epirubicin—urinary bladder cancer	0.00338	0.00338	CcSEcCtD
Methylergometrine—Headache—Gemcitabine—urinary bladder cancer	0.00337	0.00337	CcSEcCtD
Methylergometrine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00336	0.00336	CcSEcCtD
Methylergometrine—Vomiting—Fluorouracil—urinary bladder cancer	0.00336	0.00336	CcSEcCtD
Methylergometrine—Rash—Fluorouracil—urinary bladder cancer	0.00333	0.00333	CcSEcCtD
Methylergometrine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00333	0.00333	CcSEcCtD
Methylergometrine—Headache—Fluorouracil—urinary bladder cancer	0.00331	0.00331	CcSEcCtD
Methylergometrine—Nausea—Gemcitabine—urinary bladder cancer	0.00319	0.00319	CcSEcCtD
Methylergometrine—Vomiting—Cisplatin—urinary bladder cancer	0.00319	0.00319	CcSEcCtD
Methylergometrine—Rash—Cisplatin—urinary bladder cancer	0.00316	0.00316	CcSEcCtD
Methylergometrine—Dermatitis—Cisplatin—urinary bladder cancer	0.00316	0.00316	CcSEcCtD
Methylergometrine—Diarrhoea—Etoposide—urinary bladder cancer	0.00314	0.00314	CcSEcCtD
Methylergometrine—Nausea—Fluorouracil—urinary bladder cancer	0.00314	0.00314	CcSEcCtD
Methylergometrine—Tinnitus—Doxorubicin—urinary bladder cancer	0.00313	0.00313	CcSEcCtD
Methylergometrine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00311	0.00311	CcSEcCtD
Methylergometrine—Dizziness—Etoposide—urinary bladder cancer	0.00304	0.00304	CcSEcCtD
Methylergometrine—Muscle spasms—Epirubicin—urinary bladder cancer	0.00303	0.00303	CcSEcCtD
Methylergometrine—Nausea—Cisplatin—urinary bladder cancer	0.00298	0.00298	CcSEcCtD
Methylergometrine—Convulsion—Methotrexate—urinary bladder cancer	0.00292	0.00292	CcSEcCtD
Methylergometrine—Vomiting—Etoposide—urinary bladder cancer	0.00292	0.00292	CcSEcCtD
Methylergometrine—Rash—Etoposide—urinary bladder cancer	0.0029	0.0029	CcSEcCtD
Methylergometrine—Dermatitis—Etoposide—urinary bladder cancer	0.00289	0.00289	CcSEcCtD
Methylergometrine—Headache—Etoposide—urinary bladder cancer	0.00288	0.00288	CcSEcCtD
Methylergometrine—Chest pain—Methotrexate—urinary bladder cancer	0.00287	0.00287	CcSEcCtD
Methylergometrine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00281	0.00281	CcSEcCtD
Methylergometrine—Palpitations—Epirubicin—urinary bladder cancer	0.00279	0.00279	CcSEcCtD
Methylergometrine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00275	0.00275	CcSEcCtD
Methylergometrine—Convulsion—Epirubicin—urinary bladder cancer	0.00273	0.00273	CcSEcCtD
Methylergometrine—Nausea—Etoposide—urinary bladder cancer	0.00273	0.00273	CcSEcCtD
Methylergometrine—Hypertension—Epirubicin—urinary bladder cancer	0.00272	0.00272	CcSEcCtD
Methylergometrine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.0027	0.0027	CcSEcCtD
Methylergometrine—Chest pain—Epirubicin—urinary bladder cancer	0.00269	0.00269	CcSEcCtD
Methylergometrine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00266	0.00266	CcSEcCtD
Methylergometrine—Palpitations—Doxorubicin—urinary bladder cancer	0.00258	0.00258	CcSEcCtD
Methylergometrine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00257	0.00257	CcSEcCtD
Methylergometrine—Hypotension—Methotrexate—urinary bladder cancer	0.00257	0.00257	CcSEcCtD
Methylergometrine—Convulsion—Doxorubicin—urinary bladder cancer	0.00253	0.00253	CcSEcCtD
Methylergometrine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00252	0.00252	CcSEcCtD
Methylergometrine—Hypertension—Doxorubicin—urinary bladder cancer	0.00252	0.00252	CcSEcCtD
Methylergometrine—Tachycardia—Epirubicin—urinary bladder cancer	0.00251	0.00251	CcSEcCtD
Methylergometrine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00249	0.00249	CcSEcCtD
Methylergometrine—Chest pain—Doxorubicin—urinary bladder cancer	0.00248	0.00248	CcSEcCtD
Methylergometrine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00247	0.00247	CcSEcCtD
Methylergometrine—Dyspnoea—Methotrexate—urinary bladder cancer	0.00245	0.00245	CcSEcCtD
Methylergometrine—Hypotension—Epirubicin—urinary bladder cancer	0.00241	0.00241	CcSEcCtD
Methylergometrine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Methylergometrine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00234	0.00234	CcSEcCtD
Methylergometrine—Tachycardia—Doxorubicin—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Methylergometrine—Paraesthesia—Epirubicin—urinary bladder cancer	0.00231	0.00231	CcSEcCtD
Methylergometrine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Methylergometrine—Dyspnoea—Epirubicin—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00225	0.00225	CcSEcCtD
Methylergometrine—Hypotension—Doxorubicin—urinary bladder cancer	0.00223	0.00223	CcSEcCtD
Methylergometrine—Abdominal pain—Methotrexate—urinary bladder cancer	0.00217	0.00217	CcSEcCtD
Methylergometrine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00214	0.00214	CcSEcCtD
Methylergometrine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00212	0.00212	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00211	0.00211	CcSEcCtD
Methylergometrine—Abdominal pain—Epirubicin—urinary bladder cancer	0.00204	0.00204	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Methylergometrine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00188	0.00188	CcSEcCtD
Methylergometrine—Diarrhoea—Methotrexate—urinary bladder cancer	0.00188	0.00188	CcSEcCtD
Methylergometrine—Dizziness—Methotrexate—urinary bladder cancer	0.00182	0.00182	CcSEcCtD
Methylergometrine—Diarrhoea—Epirubicin—urinary bladder cancer	0.00176	0.00176	CcSEcCtD
Methylergometrine—Vomiting—Methotrexate—urinary bladder cancer	0.00175	0.00175	CcSEcCtD
Methylergometrine—Rash—Methotrexate—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Methylergometrine—Dermatitis—Methotrexate—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Methylergometrine—Headache—Methotrexate—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Methylergometrine—Dizziness—Epirubicin—urinary bladder cancer	0.0017	0.0017	CcSEcCtD
Methylergometrine—Vomiting—Epirubicin—urinary bladder cancer	0.00164	0.00164	CcSEcCtD
Methylergometrine—Nausea—Methotrexate—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Methylergometrine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Methylergometrine—Rash—Epirubicin—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Methylergometrine—Dermatitis—Epirubicin—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Methylergometrine—Headache—Epirubicin—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Methylergometrine—Dizziness—Doxorubicin—urinary bladder cancer	0.00158	0.00158	CcSEcCtD
Methylergometrine—Nausea—Epirubicin—urinary bladder cancer	0.00153	0.00153	CcSEcCtD
Methylergometrine—Vomiting—Doxorubicin—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Methylergometrine—Rash—Doxorubicin—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Methylergometrine—Dermatitis—Doxorubicin—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Methylergometrine—Headache—Doxorubicin—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Methylergometrine—Nausea—Doxorubicin—urinary bladder cancer	0.00141	0.00141	CcSEcCtD
